Taisho-controlled pharma giant DHG posts 9.4% net profit surge in 2025

DHG Pharmaceutical JSC (HoSE: DHG), one of the leading pharmaceutical firms in Vietnam, reported audited net profit of VND852 billion ($32.35 million) in 2025, down 5% from its pre-audit figure, as additional tax obligations and provisions weighed on earnings.

After audit adjustments, net profit still rose 9.4% compared to 2024’s VND779 billion ($29.58 million), reflecting steady demand in Vietnam’s pharmaceutical market despite rising regulatory and compliance costs.

According to the audited financial statements, the company recorded net revenue of VND5.27 trillion ($199.97 million), unchanged from earlier disclosures, while gross profit reached VND2.51 trillion ($95.14 million), down slightly by VND6 billion ($227,800).

Despite the downward adjustment, the firm exceeded the year’s profit target by 5%, underscoring resilient operating performance.

The audit highlighted the impact of the parliament’s Resolution 107/2023/QH15, which introduces a 15% global minimum corporate tax rate for large multinational-backed firms.

With Japan’s Taisho Pharmaceutical holding a controlling 51.01% stake, DHG had previously benefited from preferential tax rates below the 15% threshold. This triggered additional tax liabilities under the new mechanism.

As a result, the company booked VND33.01 billion ($1.25 million) in additional corporate tax for 2025, VND21.98 billion ($834,500) in back payments for 2024, and VND1.4 billion ($53,150) paid on behalf of Taisho Vietnam.

Beyond tax adjustments, DHG increased provisions related to environmental obligations. The company set aside an additional VND38.1 billion ($1.45 million) for site restoration and cleanup, bringing total long-term provisions for this purpose to VND81.46 billion ($3.09 million) by end-2025. It also recorded VND4 billion ($151,870) in short-term expenses tied to recycling and packaging treatment.

Separately, total revenue from sales and services surpassed VND6 trillion ($222.8 million) for the first time, reaching VND6.14 trillion ($233 million), up more than 7% year-on-year.

DHG shares ended up 0.3% to VND100,100 ($3.8) each on Tuesday.

  • Related Posts

    Piramal Pharma Gets 3 USFDA Observations at US Facility

    New Delhi: Piramal Pharma Limited has informed stock exchanges that the United States Food and Drug Administration (US FDA) conducted a Good Manufacturing Practices (GMP) inspection at the company’s Sellersville…

    Eli Lilly pauses Indian obesity awareness campaign after regulatory notices

    Eli Lilly has paused an obesity awareness campaign in India in response to a regulatory notice regarding advertising rules for prescription medicines, Reuters reports. In March, India’s Central Drugs Standard…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Piramal Pharma Gets 3 USFDA Observations at US Facility

    Piramal Pharma Gets 3 USFDA Observations at US Facility

    Eli Lilly pauses Indian obesity awareness campaign after regulatory notices

    Eli Lilly pauses Indian obesity awareness campaign after regulatory notices

    Kota: Uproar After 4 Women Die in Government Hospital; Relatives Refuse to Take Bodies

    Kota: Uproar After 4 Women Die in Government Hospital; Relatives Refuse to Take Bodies

    ICMR transfers three Indigenous Medical Technologies to Industry at National Technology Day 2026

    ICMR transfers three Indigenous Medical Technologies to Industry at National Technology Day 2026

    Will ‘Epidemic’ of Bridge Collapse in Bihar halt with new Minister in?

    Will ‘Epidemic’ of Bridge Collapse in Bihar halt with new Minister in?

    Patient dies after oxygen supply stops in ambulance

    Patient dies after oxygen supply stops in ambulance